ArticleCase reports in urology2023

Response of Patients with Taxane-Refractory Advanced Urothelial Cancer to Enfortumab Vedotin, a Microtubule-Disrupting Agent.

Makito Miyake et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.